Literature DB >> 9699656

Influence of N-methyl-N-nitrosourea, testosterone, and N-(4-hydroxyphenyl)-all-trans-retinamide on prostate cancer induction in Wistar-Unilever rats.

D L McCormick1, K V Rao, L Dooley, V E Steele, R A Lubet, G J Kelloff, M C Bosland.   

Abstract

The influence of chemical carcinogen, hormonal stimulation, and chronic dietary administration of the synthetic retinoid, N-(4-hydroxyphenyl)-all-trans-retinamide (4-HPR), on the induction of prostate cancer in male Wistar-Unilever rats was determined. Three different tumor induction regimens were used: (a) a single i.v. dose of 50 mg of N-methyl-N-nitrosourea (MNU) per kg body weight, followed by chronic androgen stimulation via s.c. implantation of two silastic capsules containing 40 mg testosterone each; (b) a single i.v. dose of 50 mg of MNU per kg body weight (no testosterone treatment); and (c) chronic androgen stimulation with implanted testosterone capsules (no MNU treatment). In a fourth series of animals, the incidence of spontaneous prostate tumors was determined in groups of rats receiving neither carcinogen nor hormone stimulation. Within each series, parallel groups of animals were fed a control (vehicle-supplemented) diet or control diet supplemented with 4-HPR beginning 1 day after carcinogen administration; retinoid administration was continuous until termination of the study at 450 days. The incidence of accessory sex gland cancer in rats treated sequentially with MNU + testosterone was >60%, in comparison with cancer incidences of <20% in rats receiving MNU only and <5% in rats treated with testosterone only. No spontaneous accessory sex gland tumors were observed in rats receiving no carcinogen and no testosterone. Tumor induction in the accessory sex glands by MNU + testosterone was relatively specific for the prostate: the incidence of carcinoma of the dorsolateral/anterior prostate was more than 5-fold greater than the incidence of cancer present only in the seminal vesicle. 4-HPR conferred no protection against cancer induction in the prostate by any regimen of MNU and/or testosterone. These results demonstrate the importance of both carcinogen exposure and hormone stimulation on the induction of neoplasia in the prostate of Wistar-Unilever rats.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9699656

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  Selenomethionine and alpha-tocopherol do not inhibit prostate carcinogenesis in the testosterone plus estradiol-treated NBL rat model.

Authors:  Nur Ozten; Lori Horton; Salamia Lasano; Maarten C Bosland
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-23

2.  Effects of Black Raspberries and Their Constituents on Rat Prostate Carcinogenesis and Human Prostate Cancer Cell Growth In Vitro.

Authors:  Jillian N Eskra; Alaina Dodge; Michael J Schlicht; Maarten C Bosland
Journal:  Nutr Cancer       Date:  2019-08-12       Impact factor: 2.900

Review 3.  A perspective on the role of estrogen in hormone-induced prostate carcinogenesis.

Authors:  Maarten C Bosland
Journal:  Cancer Lett       Date:  2012-08-29       Impact factor: 8.679

4.  Null activity of selenium and vitamin e as cancer chemopreventive agents in the rat prostate.

Authors:  David L McCormick; K V N Rao; William D Johnson; Maarten C Bosland; Ronald A Lubet; Vernon E Steele
Journal:  Cancer Prev Res (Phila)       Date:  2010-02-09

5.  Modulation of the malignant phenotype of human prostate cancer cells by N-(4-hydroxyphenyl)retinamide (4-HPR).

Authors:  M M Webber; D Bello-DeOcampo; S Quader; N D Deocampo; W S Metcalfe; R M Sharp
Journal:  Clin Exp Metastasis       Date:  1999-05       Impact factor: 5.150

6.  L-selenomethionine does not protect against testosterone plus 17β-estradiol-induced oxidative stress and preneoplastic lesions in the prostate of NBL rats.

Authors:  Nur Özten; Michael Schlicht; Alan M Diamond; Maarten C Bosland
Journal:  Nutr Cancer       Date:  2014-04-28       Impact factor: 2.900

7.  Words of wisdom. Re: Testosterone treatment is a potent tumor promoter for the rat prostate.

Authors:  Jason M Scovell; Peter Butler; Ranjith Ramasamy; Dolores J Lamb
Journal:  Eur Urol       Date:  2015-04       Impact factor: 20.096

8.  Joint effects of inflammation and androgen metabolism on prostate cancer severity.

Authors:  Timothy R Rebbeck; Hanna Rennert; Amy H Walker; Saarene Panossian; Teo Tran; Kyle Walker; Elaine Spangler; Margerie Patacsil-Coomes; Rajeev Sachdeva; Alan J Wein; S Bruce Malkowicz; Charnita Zeigler-Johnson
Journal:  Int J Cancer       Date:  2008-09-15       Impact factor: 7.396

9.  Is There a Future for Chemoprevention of Prostate Cancer?

Authors:  Maarten C Bosland
Journal:  Cancer Prev Res (Phila)       Date:  2016-04-20

10.  Testosterone treatment is a potent tumor promoter for the rat prostate.

Authors:  Maarten C Bosland
Journal:  Endocrinology       Date:  2014-09-23       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.